Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (211-220 of 289) with videos related to

Pageof 29
Sort By:
Clinical Genitourinary Cancer|September 19, 2015
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient ProgrammeFrancesca Maines, Orazio Caffo, Ugo De Giorgi, et al.
BJU International|July 4, 2014
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2024
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trialVincenzo Nasca, Natalie Prinzi, Jorgelina Coppa, et al.
European Urology Oncology|April 29, 2025
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA StudyMartina Buffoni, Alberto Dalla Volta, Francesca Valcamonico, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Pageof 29

Showing results (211-220 of 289) with videos related to

Sort By:
Pageof 29
Clinical Genitourinary Cancer|September 19, 2015
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient ProgrammeFrancesca Maines, Orazio Caffo, Ugo De Giorgi, et al.
BJU International|July 4, 2014
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2024
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trialVincenzo Nasca, Natalie Prinzi, Jorgelina Coppa, et al.
European Urology Oncology|April 29, 2025
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA StudyMartina Buffoni, Alberto Dalla Volta, Francesca Valcamonico, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Pageof 29